EPAS1 and neoplasm: Preclinical results on a mouse xenograft model of clear cell Renal Cell Carcinoma (ccRCCs), demonstrated that PT2385 has potent antitumor efficacy in terms of decreased expression of HIF-2α target genes, decreased circulating human VEGF-A protein, and increased tumor cell apoptosis as well as tumor regression [38].